2 results
Approved WMOCompleted
Primary Objective:To induce clinical response (CDAI decrease from baseline * 100 points) and/or remission(CDAI <150) following 12 weeks of treatment with one of two active doses ofGSK1605786A for qualification of subjects for enrolment into a…
Approved WMOCompleted
The purpose of the study is to assess the concentrations of bevacizumab in the blood at different times after the volunteers have been administered MYL-14020 or Avastin® . In addition, it will be investigated to what extent MYL-10420 is tolerated.…